What are the top late-breaking trials from #TCT2023?

TCT 2023 — Join interventional cardiologists, Prof Nicolas Van Mieghem and Dr Joost Daemen from the Thoraxcenter as they unpack the most impactful late-breaking clinical trials and science data from this year's Transcatheter Cardiovascular Therapeutics Conference.

Dive into this practical and engaging discussion and learn more about the latest data for practice and for research.

We value your opinion! Share your feedback by commenting on this page or sending us an email at info@radcliffe-group.com.

Trials covered:
00:20 - PARTNER 3 Low-Risk: Five-Year Clinical and Echocardiographic Outcomes
01:47 - EVOLUT Low-Risk: Four-Year Outcomes From the EVOLUT Low Risk Trial
04:02 - ALIGN-AR: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement
06:18 - VIVA: Transcatheter versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annuli
08:19 - AGENT IDE: Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT
11:56 - DCB-ACS: Drug-Coated Balloon for Acute Coronary Syndromes
14:06 - T-PASS: Less Than 1-month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy after Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome
16:40 - WATCH TAVR: Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve
19:20 - TRILUMINATE: Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation
21:13 - TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients With Severe Tricuspid Regurgitation
23:23 - PICSO-AMI-I: Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction
26:07 - RADIANCE: Individual Patient-data Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure at 6 Months

View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up

In this profound episode of Parallax, Dr Ankur Kalra welcomes Dr Pam Taub, Professor of Medicine and Director of Preventive Cardiology at UC San Diego, for an enlightening conversation about integrating spirituality, purpose, and scientific curiosity in cardiovascular practice.

Dr Taub shares her unique philosophical foundation, shaped by exposure to diverse religions in South India. This experience fostered her belief that all faiths fundamentally center on being a good person and serving others. She explores how this spiritual perspective transforms medicine from a profession into a sacred calling, where patient interactions become profound privileges that fuel her desire to make meaningful impact beyond individual achievements.

The episode highlights Dr Taub's groundbreaking work with POTS (Postural Orthostatic Tachycardia Syndrome), demonstrating how scientific curiosity serves as a spiritual path. Her research journey—from recognizing misdiagnosed conditions to conducting the first clinical trial for ivabradine in POTS—exemplifies how deeper questioning and evidence-based inquiry can transform patient lives on a broader scale. The episode also explores Dr Taub's research on time-restricted eating, connecting modern scientific evidence to fasting practices across many faiths.

Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio

Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.


EP 136: The Sacred and the Scientific: Integrating Spirituality in Cardiovascular Care

Explore the Top Trials from EuroPCR 25 with Insights from the Thoraxcenter!

Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at EuroPCR.

In this comprehensive EuroPCR review, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions.

00:18 - UK TAVI
03:22 - ACURATE IDE
06:10 - COMPARE TAVI
07:21 - PROTECTED TAVR and BHF PROTECT TAVI Meta Analyses
11:51 - PROVISION
14:35 - REPEAT QFR
16:44 - FAITAVI
19:49 - ILIAS ANOCA
22:20 - CAREER
26:20 - RETRIEVE AMI
28:06 - ICARE-OFDI
32:28 - COMPARE-ABSORB
33:20 - BIOADAPTOR RCT
34:22 - PERFECT PSP
37:34 - bRIGHT
39:40 - TRINITY
41:45 - AMEND

View from the Thoraxcenter: EuroPCR 25 Late-breaking Science Wrap Up

Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran

In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Michelle O'Donoghue, cardiologist at Brigham and Women's Hospital and co-author of the recently updated AHA/ACC acute coronary syndrome guidelines. Together, they explore the revolutionary changes reshaping ACS management in 2025.

Dr O'Donoghue shares insights from the landmark guideline development process that unified non-ST elevation ACS and ST elevation MI recommendations into a single comprehensive document. The conversation covers game-changing updates including new risk stratification approaches, the shift toward selective invasive strategies, and the introduction of bivalirudin as an alternative anticoagulation option.

The discussion highlights the groundbreaking "lower is better" approach to LDL management with new targets below 55 mg/dL, evolving antiplatelet therapy strategies, and the emerging role of ticagrelor monotherapy. Dr O'Donoghue also addresses future directions in cardiovascular care, from GLP-1 agonists to mechanical circulatory support devices, emphasizing how these guidelines represent a fundamental shift toward more personalized, evidence-based ACS management.

Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. 

Host: @AnkurKalraMD and produced by: @RadcliffeCardio
Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

EP 137: Redefining ACS Care: From Guideline Updates to Clinical Excellence

In this insightful episode of Parallax, Dr Ankur Kalra explores the emerging field of cardiac epigenetics with Dr Manuel Rosa-Garrido, assistant professor of medicine at the University of Alabama in Birmingham. Their conversation examines how the three-dimensional organization of DNA within the cell nucleus influences heart disease development beyond traditional genetic sequencing.

Dr Rosa-Garrido shares his pioneering work using Hi-C technology to map genome structure, revealing that DNA arrangement plays a crucial role in cardiac pathology. The discussion covers key concepts including chromatin loops, topologically associating domains, and compartmentalization—explaining how these structures regulate gene expression and how their disruption contributes to cardiovascular disease.

The episode explores practical implications for clinical practice, from early biomarker identification to potential CRISPR-based therapies that could target chromatin structure. Dr Rosa-Garrido outlines how this research could transform cardiovascular care within the next decade, offering new approaches to both inherited cardiomyopathies and environmentally-influenced conditions like atherosclerosis.

Valuable insights for cardiologists interested in precision medicine and the evolving understanding of how genetic architecture influences cardiovascular risk and treatment strategies.

Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio

Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

EP 138: Mapping the Heart's Hidden Code: How 3D Chromatin Structure Shapes Cardiac Disease

In this essential episode of Parallax, Dr Ankur Kalra is joined by Dr Carolyn Ho, Professor of Medicine at Harvard Medical School and Medical Director of the Cardiovascular Genetics Program at Brigham and Women's Hospital, for a comprehensive discussion on how genetic testing is reshaping hypertrophic cardiomyopathy management.

The conversation explores the VANISH HCM trial results, which showed that valsartan can slow disease progression in young, asymptomatic individuals with early sarcomeric HCM. Dr Ho discusses how this evidence influenced the 2024 HCM guidelines and created new opportunities for disease-modifying therapy before clinical symptoms appear. The episode also examines emerging gene-based therapeutics, from current adeno-associated virus approaches to future CRISPR technologies that could address the underlying genetic causes of HCM.

Dr Ho addresses practical considerations for clinicians, including when to initiate genetic testing, how to manage family screening, and the promise of AI-assisted screening tools. The discussion highlights both current therapeutic options and the evolving landscape of precision medicine in inherited cardiovascular disease.

Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio
Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

EP 139: The Genetic Revolution in HCM: Mapping Family Risk to Targeted Treatment

Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve.

ESC Congress 2025 Hot Line Trials Discussed:
00:25 - DOUBLE-CHOICE
03:03 - VANTAGE
05:03 - VICTOR
06:28 - VICTORIA
07:58 - DIGIT HF
10:19 DAPA ACT HF-TIMI 68
12:35 REBOOT-CNIC
14:07 BETAMI DANBLOCK
16:03 REFINE ICD
18:05 OPTION STEMI
20:43 DUAL ACS
22:46 NEO MINDSET
24:53 TARGET FIRST
26:59 OUTREACH
29:29 FIRE
31:40 AI GATEKEEPER
22:42 LAA CLOSURE

Stay tuned for Radcliffe Cardiology’s in-depth coverage of these and other pivotal trials from ESC Congress 2025.

View from the Thoraxcenter: What's Hot at ESC 25?

In this compelling episode of Parallax, Dr Ankur Kalra sits down with Dr Anandita Kulkarni, preventive cardiologist at Baylor Scott and White Heart Hospital, for an eye-opening conversation about addressing cardiovascular disparities in South Asian populations through the innovative Dilwale registry.

Dr Kulkarni tells the story of returning to her Texas community to serve South Asian patients and her determination to create meaningful change through data. What started as a local initiative grew into something much larger: a comprehensive registry of over 31,000 South Asian patients that's revealing critical insights about heart disease in this underserved population.

Beyond the clinical data, this episode delves into the practical challenges of culturally informed preventive care. Dr Kulkarni shares insights on addressing barriers to physical activity within South Asian communities, helping patients navigate dietary changes while respecting cultural food traditions, and the delicate work of motivating lifestyle modifications in a population already facing higher cardiovascular risks. Her patient-centered approach demonstrates how combining population-level research with deep cultural understanding can fundamentally improve both individual outcomes and community health.

Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio

Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts

EP 140: Breaking Barriers in South Asian Heart Health: The Dilwale Registry Revolution

The Radcliffe Cardiology Podcast brings you the latest advancements, research and best practices in the field of cardiology. Each episode features expert insights and engaging discussions with leading healthcare professionals, covering a breadth of topics in cardiovascular science. 

Our podcast aims to build on the best science, with key takeaways from the top cardiology conferences and recent publications from our journals.